Cholesteryl ester transfer protein (CETP) inhibitors are new class of drugs to treat cardiovascular diseases, specifically CETP inhibitors improves high-density lipoproteins (HDL) level in blood.
Research of CETP inhibitors might have started somewhere around 1990 to 1995 and PD 140195 may be the first compound to evaluated for CETP inhobition.
There are three notable molecules are in development pipeline by different originators. Japan Tabacco and Roche develops JTT-705 (Dalcetrapib), Pfizer (Torcetrapib) and Merck (Anacetrapib).
Pfizer initiated a development of CETP inhibitors which is named Torcetrapib, presently development of Toecetrapib is abandoned due to off-target effect (increase in blood pressure). Delcetrapib and Anacetrapib are presently in progress of positive development. Merck has now presented positive trial data on Anacetrapib (News).
In next post, i will update patent status on CETP inhibitors (to continue…)